Drug Trial Radar · NCT04379596
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
452
Actual
Start
Jun 3, 2020
Primary completion
May 4, 2027
Study completion May 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- May 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-expressing gastric, GEJ and esophageal cancer patients who have not received prior treatment for advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the potential to become a therapeutic option for this patient population.
Conditions
- Gastric Cancer
Interventions
Fluorouracil (5-FU)Drug
5-FU: administered as an IV infusion
CapecitabineDrug
Capecitabine: administered orally
DurvalumabBiological
Durvalumab: administered as an IV infusion
OxaliplatinDrug
Oxaliplatin: administered as an IV infusion
TrastuzumabBiological
Trastuzumab: administered as an IV infusion
Trastuzumab deruxtecanDrug
T-DXd: administered as an IV infusion
CisplatinDrug
Cisplatin: administered as an IV infusion
PembrolizumabBiological
Pembrolizumab: administered as an IV infusion
VolrustomigBiological
Volrustomig: administered as an IV infusion
RilvegostomigBiological
Rilvegostomig: administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
- Part 1: Ocurrence of dose-limiting toxicities (DLTs)Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
- Part 1: Changes from baseline in laboratory parametersTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
- Part 1: Changes from baseline in vital signsTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
- Part 1: Changes from baseline in electrocardiogram (ECG) resultsTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
- Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)Time frame: (Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months
Locations
71 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
New York, New York
Research Site
Houston, Texas
Research Site
Londrina, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Santa Maria, Brazil
Research Site
São Jose Do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Hefei, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Wuhan, China
Research Site
Zhengzhou, China
Research Site
Frankfurt, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Leipzig, Germany
Research Site
Mannheim, Germany
Research Site
München, Germany
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Padova, Italy
Research Site
Roma, Italy
Research Site
Verona, Italy
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Amsterdam, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Gdansk, Poland
Research Site
Konin, Poland
Research Site
Koszalin, Poland
Research Site
Krakow, Poland
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.